TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03493386
Drug: Daprodustat 2 mg tablet
Normalized name: daprodustat
DrugBank: Daprodustat (DB11682)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Daprodustat is available as 2 mg tablet. Subjects will receive daprodustat orally as tablet. A single dose of 2 tablets of 2 mg daprodustat will be administered in a fasted state during Part 1 of the study.
Study: NCT03493386
Drug: Daprodustat 4 mg tablet
Normalized name: daprodustat
DrugBank: Daprodustat (DB11682)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Daprodustat is available as 4 mg tablet. Subjects will receive daprodustat orally as tablet. A single dose of 4 mg daprodustat will be administered in a fasted state during Part 1 and in fed and fasted state in Part 2 of the study.
Study: NCT02494973
Drug: Oxaliplatin HAI
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin 85 mg/m² in 2 hours HAI day (D)1,
Study: NCT02494973
Drug: Oxaliplatin IV
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin 85 mg/m² in 2 hours IV day (D)1,
Study: NCT02423525
Drug: Afatinib
Normalized name: Afatinib
DrugBank: Afatinib (DB08916)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00753727
Drug: Sunitinib malate
Normalized name: Sunitinib Malate
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sunitinib dose 50 mg/day orally for 2 weeks prior to radiotherapy. Treatment Dose Levels during radiotherapy: Dose level 0: Sunitinib 50mg/day for 2 weeks prior to radiotherapy, followed by 25mg/day given concurrently with radiotherapy; Dose level 1: Sunitinib 50mg/day for 2 weeks prior to radiotherapy, followed by 37.5mg/day given concurrently with radiotherapy; Dose level -1: Sunitinib 37.5mg/day for 2 weeks prior to radiotherapy, followed by 37.5mg/day given concurrently with radiotherapy. Dose escalation/de-escalation: first 6 patients will be accrued at dose level 0. The dose levels at which subsequent patients will be accrued will be determined using a dose modification schedule.
Study: NCT00277810
Drug: lecozotan SR (SRA-333)
Normalized name: Lecozotan
DrugBank: Lecozotan (DB12540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: one of 3 doses of lecozotan sr dose for 6 months as an extension to a 6 month study with patients required to be on a cholinesterase inhibitor 2, 5, or 10 mg of lecozotan sr
Study: NCT00418600
Drug: doxercalciferol capsules, Hectorol®
DrugBank: Doxercalciferol (DB06410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hectorol capsules at 1.5 times current injection dose
Study: NCT00418600
Drug: doxercalciferol capsules, Hectorol® capsules
DrugBank: Doxercalciferol (DB06410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hectorol capsules at 2.0 times current injection dose
Study: NCT00814580
Drug: Tapentadol IR
DrugBank: Tapentadol (DB06204)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First dose: one 50 mg capsule (a re-dose of 50 mg is permitted as soon as one hour after the first dose on Day 1, if needed) Subsequent doses: one or two capsules (50 mg or 100 mg) every 4 to 6 hours as needed
Study: NCT00814580
Drug: Oxycodone IR
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: First dose: one 5 mg capsule (a re-dose of 5 mg is permitted as soon as one hour after the first dose on Day 1, if needed Subsequent doses: one or two capsules (5 mg or 10 mg) every 4 to 6 hours as needed
Study: NCT02726074
Drug: Perampanel
Normalized name: Perampanel
DrugBank: Perampanel (DB08883)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03362281
Drug: Ilaprazole
Normalized name: ilaprazole
DrugBank: Ilaprazole (DB11964)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg ilaprazole daily (at day 1-3) through intravenous infusion within 30min with first dose doubling.
Study: NCT01244230
Drug: fexofenadine/Allegra (M016455)
DrugBank: Fexofenadine (DB00950)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form:dry syrup formulation to be suspended in water~Route of administration: oral
Study: NCT03362281
Drug: Omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 mg omeprazole twice daily (at day 1-3) through intravenous infusion within 30min.
Study: NCT03362281
Drug: Ilaprazole tablet
Normalized name: ilaprazole
DrugBank: Ilaprazole (DB11964)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Since 4th day, those patients were changed to take oral ilaprazole tablets 10mg each day till 30th day
Study: NCT01222975
Drug: Risperidone
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: orally disintegrating tablets
Study: NCT01713582
Drug: OTX015/Birabresib
DrugBank: Birabresib (DB15189)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OTX015/Birabresib 10 mg, 20 mg, or 40 mg capsules administered orally
Study: NCT00042952
Drug: imatinib mesylate
Normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given orally
Study: NCT03261947
Drug: TAK-931
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-931 hard gelatin capsules
Study: NCT00463749
Drug: Acetylcystein
Normalized name: Acetylcysteine
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: high-dose N-Acetylcystein during PCI and for 2/day for 2 days
Study: NCT00914862
Drug: Ramelteon
Normalized name: Ramelteon
DrugBank: Ramelteon (DB00980)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ramelteon tablets, orally for one day only.
Study: NCT00809835
Drug: Galantamine
Normalized name: Galantamine
DrugBank: Galantamine (DB00674)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily 8 mg galantamine capsule
Study: NCT00205426
Drug: Natrecor
Normalized name: Natrecor
DrugBank: Nesiritide (DB04899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Natrecor will be initiated as a bolus dose of 2 mcg/kg followed by a continuous infusion via infusion pump after induction of anesthesia but prior to incision. Natrecor infusion will be started at the recommended rate of 0.01mcg/kg/min. This dose may be adjusted by the investigator(s) only based on hemodynamic monitoring and pulmonary parameters. Study drug will be infused for a minimum of 24 hours and a maximum of 96 hours.
Study: NCT03054870
Drug: Xe-133
Normalized name: XENON,XE-133
DrugBank: Xenon (DB13453)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xe-133 ventilation scintigraphy
Study: NCT03054870
Drug: Technegas
Normalized name: TECHNEGAS KIT
DrugBank: Graphite (DB18717)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Technegas ventilation scintigraphy
Study: NCT02789813
Drug: Valproic Acid
Normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Once oral administration of 500mg before exposure therapy.
Study: NCT01637974
Drug: INTERCOAT administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Applying INTERCOAT in the intrauterine cavity at the end of the hysteroscopic surgery
Study: NCT00814086
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV or intraperitoneally
Study: NCT00814086
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given intraperitoneally
Study: NCT03198741
Drug: Aspirin + clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: After randomization(6 months±2 weeks after enrollment),receive aspirin 100mg/d + clopidogrel 75mg/d for an additional 6 months. The above treatments between 6 and 12 months are double-blinded.
Study: NCT03198741
Drug: Clopidogrel monotherapy
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: After randomization(6 months±2 weeks after enrollment),receive clopidogrel 75mg/d + placebo (clopidogrel monotherapy group) for an additional 6 months. The above treatments between 6 and 12 months are double-blinded.
Study: NCT03198741
Drug: Aspirin monotherapy
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After randomization(6 months±2 weeks after enrollment),receive aspirin 100mg/d + placebo (aspirin monotherapy group) for an additional 6 months. The above treatments between 6 and 12 months are double-blinded.
Study: NCT00776646
Drug: hydrochlorothiazide 50 mg tablet
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00396045
Drug: Revlimid (CC-5013)
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03245554
Drug: Propranolol
Normalized name: Propranolol
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0 or 1 were generated by using Random software. The patient entered the placebo group if number was 0; if the random number generated was 1, then entered the propranolol group.
Study: NCT02009878
Drug: tolvaptan
Normalized name: Tolvaptan
DrugBank: Tolvaptan (DB06212)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subjects will receive a single dose of 3.75, 7.5 or 15 mg of tolvaptan on study Day 1
Study: NCT03457961
Drug: Perampanel
Normalized name: Perampanel
DrugBank: Perampanel (DB08883)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: This study collects clinical information during the first 16 weeks after the first dose of AMPA/NMDA receptor antagonist. Subjects or caregivers shall provide seizure diary which documents seizure type and seizure frequency as per usual medical care. The final visit will be based on the week-16 visit.
Study: NCT01820754
Drug: Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Neoadjuvant (Pre-Surgery): Cycles 2 and 3: Ipilimumab 10 mg/kg IV over 90 minutes~Adjuvant (Post-Surgery): Ipilimumab 10 mg/kg IV every 3 weeks times 2 doses beginning 4 weeks postoperative ( up to 10 weeks if needed for recovery)~Maintenance: Ipilimumab 10 mg/kg/IV every 12 weeks times 2 doses
Study: NCT01820754
Drug: Paclitaxel, Cisplatin, Carboplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neoadjuvant (Pre-Surgery) Cycle 1: Paclitaxel 175 mg/m2 IV over 3 hours , followed by Cisplatin 75 mg/m2 IV over 60 minutes or carboplatin AUC 6 IV over 30-60 minutes on day 1(Every 21 days x 1 cycle)~Cycles 2 and 3: Ipilimumab 10 mg/kg IV over 90 minutes, Paclitaxel 175 mg/m2 IV over 3 hours , followed by Cisplatin 75 mg/m2 IV over 60 minutes or carboplatin AUC 6 IV over 30-60 minutes on day 1(Every 21 days x 2 cycles)
Study: NCT01262482
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 130 mg/m2, IV during 2 hours on day 1 of each 21 day cycle. Number of cycles: until progression, intolerance or unacceptable toxicity develops, or until patient or investigator decide to stop the treatment.
Study: NCT01262482
Drug: Sorafenib
Normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400mg, orally, 2 times per day. Until progression, intolerance or unacceptable toxicity develops, or until patient or investigator decide to stop the treatment.
Study: NCT03062956
Drug: MYK-491 or placebo
Normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral suspension
Study: NCT00973479
Drug: Golimumab
Normalized name: Golimumab
DrugBank: Golimumab (DB06674)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will receive 2 mg/kg of golimumab intravenously over 30 ± 10 minutes. Group 1: at Weeks 0, 4, and every 8 weeks thereafter (up to Week 100). Group II: Weeks 24, 28, and every 8 weeks thereafter (up to Week 100); Early escape: at Week 16, 20 and every 8 weeks thereafter (up to Week 100).
Study: NCT01113320
Drug: Safinamide
Normalized name: Safinamide
DrugBank: Safinamide (DB06654)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Evaluable dose levels are 100 mg (8 days), 200 mg (10 days), and 300 mg (42 days). Intermediate dose levels are 150 mg (Study days 9-11) and 250 mg (Study days 23-25) and have a duration of three days. Safinamide will be provided in tablets of 50 mg in blisters. Dosing will be achieved using appropriate multiples of these tablet strengths
Study: NCT01530178
Drug: Sitagliptin
Normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: In each intervention arm the participant receives a different dose of sitagliptin.
Study: NCT04551898
Drug: BGB-DXP593
Normalized name: BGB-DXP593
DrugBank: BGB-DXP593 (DB16357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) infusion administered over 30 to 90 minutes at a dose as specified in the treatment arm
Study: NCT00328913
Drug: 5-hydroxytryptophan (food supplement)
DrugBank: Tryptophan (DB00150)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00589953
Drug: Erythropoietin
Normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 of first 10 subjects (Group 1): 400 units/kg/dose once daily for 7 days 5 of next 10 subjects (Group 2): 800 units/kg/dose once daily for 7 days 20 of next 30 subjects (Group 3): 1000 units/kg/dose once daily for 7 days administered i.v. over 1 hour.~The volume of the study drug will be 1 mL in a 1 mL Tuberculin syringe to be administered over 1 hour.
Study: NCT01000298
Drug: Amoxicillin
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: liquid amoxicillin given twice per day for 7 days
Study: NCT01000298
Drug: Cefdinir
Normalized name: Cefdinir
DrugBank: Cefdinir (DB00535)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: liquid cefdinir given twice per day for 7 days
Study: NCT00003799
Drug: oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01970176
Drug: Tadalafil
Normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tadalafil 5 mg tablet. Daily. Tadalafil dose varies from 5 mg to 20 mg for 12 weeks. If blood pressure is \>95 then subject dismissed from the Clinical Research Unit (CRU) on 2 (5 mg) tabs of tadalafil or placebo. If blood pressure is between 90 - 95 mmHg systolic, then dismiss on 1 (5 mg) tab of Tadalafil. At 2 weeks (± 5 days) if blood pressure is\> 100 than add 1 (5 mg) tab of Tadalafil to make a total of 3 (5mg) tabs of Tadalafil. At 4 weeks(± 5 days) if blood pressure is \> 100 add 1 (5 mg) tab to make a total of 4 (5 mg) tablets of Tadalafil.
Study: NCT01678417
Drug: 131I-rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03272477
Drug: Leuprorelin acetate
Normalized name: Leuprorelin acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One injection of 3,75mg every month or 4 weeks in pre-menopausal women treated with aromatase inhibitors Anastrozole or Letrozole or Exemestane, for a total of 40 weeks in the adjuvant therapy phase.
Study: NCT01631201
Drug: Rifalazil 25 milligram
Normalized name: Rifalazil
DrugBank: Rifalazil (DB04934)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 25 milligram rifalazil to be administered on Day 1.
Study: NCT00973024
Drug: JNJ-42160443 3 mg
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-42160443: type=exact number, unit=mg, number= 3, form=solution for injection, route=Subcutaneous use or Placebo: form=solution for injection, route=Subcutaneous injection. One inj of 3 mg of JNJ-42160443 or matching placebo every 4 wks for up to 104 wks.
Study: NCT00879034
Drug: Lonafarnib
Normalized name: LONAFARNIB
DrugBank: Lonafarnib (DB06448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lonafarnib capsules are to be orally administered twice per day approximately every 12 hours. Lonafarnib dosing will begin at 150 mg/m2 by mouth twice daily. Dose levels are 150, 115, 90 and 70 mg/m2. Patients experiencing significant drug related grade 3 or 4 toxicity and not responding to therapy interruption or supportive care measures will be dose reduced by one dose level.
Study: NCT02013778
Drug: HCQ
Normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00623233
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine 2500 mg/m\^2 IV over 30 minutes given on Day 1 q 14 days prior to bevacizumab until PD or unacceptable toxicity.
Study: NCT00623233
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab 10 mg/kg IV over 90 minutes at Cycle 1; infusion time may have been decreased for subsequent cycles. (For example, if the first infusion was tolerated without an infusion-associated adverse event \[AE\], the second infusion was delivered over 60 minutes. If the 60-minute infusion was well tolerated, all subsequent infusions were delivered over 30 minutes.)~Bevacizumab 10 mg/kg initially over 90 minutes given on Day 1 q 14 days until PD or unacceptable toxicity.
Study: NCT00931125
Drug: ranibizumab and vitrectomy
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: ranibizumab 10mg/ml intravitreal injection, 0,05 ml
Study: NCT00973024
Drug: JNJ-42160443 1 mg
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-42160443: type=exact number, unit=mg, number= 1, form=solution for injection, route=Subcutaneous use or Placebo: form=solution for injection, route=Subcutaneous injection. One inj of 1 mg of JNJ-42160443 or matching placebo every 4 wks for up to 104 wks.
Study: NCT05202899
Drug: sugammadex
Normalized name: Sugammadex
DrugBank: Sugammadex (DB06206)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The use of sugammadex
Study: NCT03050450
Drug: 25 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®)
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Drug: Lenalidomide 25 mg/m2 days 1-21 of a 28 days cycle Drug: Vorinostat 180 mg/m2 days 1-7 and 15-21 of a 28 day cycle
Study: NCT03050450
Drug: 50 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®)
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Drug: Lenalidomide 50 mg/m2 days 1-21 of a 28 days cycle Drug: Vorinostat 180 mg/m2 days 1-7 and 15-21 of a 28 day cycle
Study: NCT03050450
Drug: 100 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®)
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Drug: Lenalidomide 100 mg/m2 days 1-21 of a 28 days cycle Drug: Vorinostat 180 mg/m2 days 1-7 and 15-21 of a 28 day cycle
Study: NCT00973024
Drug: JNJ-42160443 6 mg/3mg
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-42160443: type= exact number, unit= mg, number= 3 and 6, form=solution for injection, route= Subcutaneous use or Placebo: form= solution for injection, route= Subcutaneous injection. 1 inj of 6 mg of JNJ-42160443 on Day 1 followed by 1 inj of 3 mg or matching placebo every 4 wks for up to 104 wks.
Study: NCT03050450
Drug: 150 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®)
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Drug: Lenalidomide 150 mg/m2 days 1-21 of a 28 days cycle Drug: Vorinostat 180 mg/m2 days 1-7 and 15-21 of a 28 day cycle
Study: NCT03050450
Drug: 150 mg/m2 Lenalidomide (Revlimid®) and 230 mg/m2 Vorinostat (Zolinza®)
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Drug: Lenalidomide 150 mg/m2 days 1-21 of a 28 days cycle Drug: Vorinostat 230 mg/m2 days 1-7 and 15-21 of a 28 day cycle
Study: NCT00907322
Drug: Dimebon
Normalized name: Dimebon
DrugBank: Latrepirdine (DB11725)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet; 20 mg Dimebon, single dose
Study: NCT00907322
Drug: Dimebon
Normalized name: Dimebon
DrugBank: Latrepirdine (DB11725)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet; 40 mg Dimebon, single dose
Study: NCT00973024
Drug: JNJ-42160443 10 mg
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-42160443 10 mg: type=exact number, unit=mg, number= 10, form=solution for injection, route=Subcutaneous use or Placebo: form=solution for injection, route=Subcutaneous injection. One inj of 10 mg of JNJ-42160443 or matching placebo every 4 wks for up to 104 wks.
Study: NCT00907322
Drug: Dimebon
Normalized name: Dimebon
DrugBank: Latrepirdine (DB11725)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet; 60 mg Dimebon, single dose
Study: NCT00907322
Drug: Dimebon
Normalized name: Dimebon
DrugBank: Latrepirdine (DB11725)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet; placebo, single dose
Study: NCT01208324
Drug: estrogen patch
Normalized name: estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 150 subjects will be enrolled in a double blind placebo controlled study where they will be randomized to receive either treatment with 17β-estradiol (Vivelle Dot® 0.10 - 0.15 mg/day) or a look-alike placebo patch for a total of approximately 8 weeks. There will be four fMRI test sequences: two test sequences one week apart prior to estrogen treatment (ET) or placebo treatment (PT), and two sequences one week apart following approximately 6-weeks of double-blind ET or PT. During each test day, all subjects will have their blood drawn at specific time intervals and undergo a battery of cognitive testing.While on the ET or PT treatment, all subjects will be instructed to change the patch every 3.5 days.
Study: NCT01208324
Drug: Amino acids
Normalized name: Amino acids
DrugBank: Amino acids (DB09393)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 31.5 mg of amino acids or 31.5 mg of lactose will be administered to subjects on each of their 4 test days. On 2 of the test days subjects will receive the active pills (amino acids) and on the other 2 test days subjects will receive the placebo pills (lactose).
Study: NCT04004338
Drug: Kyprolis
Normalized name: Kyprolis
DrugBank: Carfilzomib (DB08889)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients receiving kyprolis (carfilzomib)
Study: NCT00570778
Drug: indacaterol/glycopyrrolate
Normalized name: indacaterol/glycopyrrolate 27.5 mcg-15.6 mcg INHALATION CAPSULE, WITH INHALATION DEVICE
DrugBank: Indacaterol (DB05039)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Inhalation capsule indacaterol/glycopyrrolate 300/50 μg inhaled once daily via a single dose dry powder inhaler for 7 days.
Study: NCT00570778
Drug: indacaterol
Normalized name: Indacaterol
DrugBank: Indacaterol (DB05039)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Inhalation capsule indacaterol supplied as 300 μg capsules inhaled once daily via a single dose dry powder inhaler for 7 days.
Study: NCT01491178
Drug: Prazaxa
Normalized name: Pradaxa
DrugBank: Dabigatran etexilate (DB06695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dabigatran etexilate
Study: NCT02014506
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40mg/M2 once daily IV on days -7 to -2